RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
PharmaResearch Co Stock

PharmaResearch Co Net Income 2024

PharmaResearch Co Net Income

104.13 B KRW

Ticker

214450.KQ

ISIN

KR7214450009

In 2024, PharmaResearch Co's profit amounted to 104.13 B KRW, a 36.02% increase from the 76.55 B KRW profit recorded in the previous year.

The PharmaResearch Co Net Income history

YEARNET INCOME (undefined KRW)
2026e152.98
2025e126.83
2024e104.13
202376.55
202240.58
202146.69
202032.77
201916.67
201814.41
201712.96
201613.91
201512.88
20148.84
20135.66

PharmaResearch Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into PharmaResearch Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by PharmaResearch Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects PharmaResearch Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of PharmaResearch Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into PharmaResearch Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing PharmaResearch Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on PharmaResearch Co’s growth potential.

PharmaResearch Co Revenue, EBIT and net profit per share

DatePharmaResearch Co RevenuePharmaResearch Co EBITPharmaResearch Co Net Income
2026e480.03 B undefined183.35 B undefined152.98 B undefined
2025e407.48 B undefined152.97 B undefined126.83 B undefined
2024e339.55 B undefined125.16 B undefined104.13 B undefined
2023261.01 B undefined92.26 B undefined76.55 B undefined
2022194.76 B undefined65.92 B undefined40.58 B undefined
2021154.08 B undefined52.49 B undefined46.69 B undefined
2020108.75 B undefined33.43 B undefined32.77 B undefined
201983.87 B undefined19.06 B undefined16.67 B undefined
201864.28 B undefined8.71 B undefined14.41 B undefined
201754.47 B undefined14.84 B undefined12.96 B undefined
201645.95 B undefined14.11 B undefined13.91 B undefined
201537.46 B undefined16.09 B undefined12.88 B undefined
201424.77 B undefined11.41 B undefined8.84 B undefined
201317.77 B undefined7.21 B undefined5.66 B undefined

PharmaResearch Co stock margins

The PharmaResearch Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of PharmaResearch Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for PharmaResearch Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the PharmaResearch Co's sales revenue. A higher gross margin percentage indicates that the PharmaResearch Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the PharmaResearch Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the PharmaResearch Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the PharmaResearch Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the PharmaResearch Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the PharmaResearch Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

PharmaResearch Co Margin History

PharmaResearch Co Gross marginPharmaResearch Co Profit marginPharmaResearch Co EBIT marginPharmaResearch Co Profit margin
2026e72.89 %38.2 %31.87 %
2025e72.89 %37.54 %31.13 %
2024e72.89 %36.86 %30.67 %
202372.89 %35.35 %29.33 %
202272.66 %33.85 %20.83 %
202170.31 %34.07 %30.3 %
202067.03 %30.74 %30.14 %
201959.74 %22.73 %19.87 %
201859.45 %13.54 %22.41 %
201766.21 %27.25 %23.79 %
201667.11 %30.69 %30.27 %
201568.8 %42.97 %34.38 %
201473.53 %46.09 %35.68 %
201369.79 %40.57 %31.86 %

PharmaResearch Co Aktienanalyse

What does PharmaResearch Co do?

PharmaResearch Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding PharmaResearch Co's Profit Margins

The profit margins of PharmaResearch Co represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of PharmaResearch Co's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating PharmaResearch Co's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

PharmaResearch Co's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When PharmaResearch Co’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about PharmaResearch Co stock

How much profit has PharmaResearch Co made this year?

PharmaResearch Co has made 104.13 B KRW this year.

How has the profit developed compared to last year?

The profit has increased by 36.02% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does PharmaResearch Co publish its earnings?

PharmaResearch Co publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of PharmaResearch Co?

The profits of PharmaResearch Co are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of PharmaResearch Co?

You can learn more about the earnings of PharmaResearch Co by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does PharmaResearch Co pay?

Over the past 12 months, PharmaResearch Co paid a dividend of 950 KRW . This corresponds to a dividend yield of about 0.43 %. For the coming 12 months, PharmaResearch Co is expected to pay a dividend of 1,044.52 KRW.

What is the dividend yield of PharmaResearch Co?

The current dividend yield of PharmaResearch Co is 0.43 %.

When does PharmaResearch Co pay dividends?

PharmaResearch Co pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of PharmaResearch Co?

PharmaResearch Co paid dividends every year for the past 12 years.

What is the dividend of PharmaResearch Co?

For the upcoming 12 months, dividends amounting to 1,044.52 KRW are expected. This corresponds to a dividend yield of 0.48 %.

In which sector is PharmaResearch Co located?

PharmaResearch Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von PharmaResearch Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of PharmaResearch Co from 4/18/2024 amounting to 950 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2023.

When did PharmaResearch Co pay the last dividend?

The last dividend was paid out on 4/18/2024.

What was the dividend of PharmaResearch Co in the year 2023?

In the year 2023, PharmaResearch Co distributed 660 KRW as dividends.

In which currency does PharmaResearch Co pay out the dividend?

The dividends of PharmaResearch Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von PharmaResearch Co

Our stock analysis for PharmaResearch Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of PharmaResearch Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.